Synucleinopathies clinical trials at University of California Health

1 in progress, 0 open to eligible people

Showing trials for

  • Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

    Sorry, not yet accepting patients

    The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily activities) decline. For each participant, the study will last one and a half years.

    at UCSD

Our lead scientists for Synucleinopathies research studies include .

Last updated: